2024 U.S. POC/Decentralized Infectious Disease Testing Market: Country Supplier Shares, Test Volume and Sales Segment Forecasts
![](/report_cover/2215/2024-us-pocdecentralized-infectious-disease-testing-market-country-supplier-shares-test-volume-n-sales-segment-forecasts_en.gif)
This new 795-page report from LeadingMarketResearch.com contains 61 tables, and provides a comprehensive analysis of the POC infectious disease testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC infectious disease testing market. RationaleThe growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.Market Segmentation Analysis%li%Review of five POC market segments, including their dynamics, trends, structure, size, growth and major suppliers.%li%Five-year test volume and reagent sales forecasts for major infectious disease tests by market segment:%li%Physician Offices/Group Practices %li%Emergency Rooms %li%Ambulatory Care Centers %li%Surgery Centers %li%Birth CentersSales and Market Share Analysis%li%Market shares of major infectious disease diagnostic reagent and instrument suppliers.Current and Emerging Products%li%Analysis of infectious disease diagnostic tests performed in POC testing locations.%li%Review of leading infectious disease testing analyzers, both currently marketed and & those in development, including their operating characteristics, features and selling prices.Technology Review%li%Emerging technologies and their applications for POC testing.%li%Comprehensive listings of companies developing or marketing coagulation & testing technologies and products, by assay.Competitive Assessments%li%Assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, joint ventures, and new products in R&D.Strategic Recommendations%li%Specific opportunities for new infectious disease testing instruments and reagent systems with potentially significant market appeal during the next five years.%li%Design criteria for POC testing products.%li%Alternative business expansion strategies.%li%Potential market entry barriers and risks.MethodologyThis report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and VPGMarketResearch's proprietary data files.
Introduction
Executive Summary
Rationale for Testing Decentralization
1. OVERVIEW
2. REGULATORY TRENDS
3. ECONOMIC TRENDS
4. DEMOGRAPHIC TRENDS
5. TECHNOLOGICAL TRENDS
6. SOCIAL TRENDS
7. QUALITY OF CARE
8. DEFENSIVE MEDICINE
9. QUALITY CONTROL ISSUES
Worldwide Market and Technology Overview
1. AIDS
2. ADENOVIRUS
3. CAMPYLOBACTER
4. CANDIDA
5. CHLAMYDIA
6. CLOSTRIDIUM DIFFICILE
7. CYTOMEGALOVIRUS
8. ENTEROVIRUSES
9. EPSTEIN-BARR VIRUS
10. GONORRHEA
11. HELICOBACTER PYLORI
12. HEPATITIS
a. Hepatitis A
b. Hepatitis B
c. Hepatitis C
d. Hepatitis D
13. HERPES SIMPLEX VIRUS
Table of Contents (continued)
14. HUMAN HERPES VIRUS-6 (HHV-6)
15. INFLUENZA VIRUSES
16. LEGIONELLA
17. LYME DISEASE
18. MEASLES (RUBEOLA)
19. MENINGITIS
20. MONONUCLEOSIS
21. MUMPS
22. MYCOPLASMA
23. PAPILLOMAVIRUSES
24. PNEUMONIA
25. RESPIRATORY SYNCYTIAL VIRUS (RSV)
26. RHEUMATOID ARTHRITIS
27. ROTAVIRUS (REOVIRUS)
28. RUBELLA (GERMAN MEASLES)
29. SALMONELLOSIS
30. SHIGELLOSIS
31. STAPHYLOCOCCUS AUREUS
32. STREPTOCOCCI
33. SYPHILIS
Instrumentation: Infectious Disease Analyzers Manufactured by:
- Abbott
- Beckman Coulter/Danaher
- bioMeriuex
- Ortho-Clinical Diagnostics
- Roche
- Siemens
- Tosoh
- Wallac, and other suppliers
Current and Emerging Technologies
1. MONOCLONAL ANTIBODIES
2. IMMUNOASSAYS
a. Technological Principle
b. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Dot Immunobinding Assays
- Capillary Immunoassays
Executive Summary
Rationale for Testing Decentralization
1. OVERVIEW
2. REGULATORY TRENDS
3. ECONOMIC TRENDS
4. DEMOGRAPHIC TRENDS
5. TECHNOLOGICAL TRENDS
6. SOCIAL TRENDS
7. QUALITY OF CARE
8. DEFENSIVE MEDICINE
9. QUALITY CONTROL ISSUES
Worldwide Market and Technology Overview
1. AIDS
2. ADENOVIRUS
3. CAMPYLOBACTER
4. CANDIDA
5. CHLAMYDIA
6. CLOSTRIDIUM DIFFICILE
7. CYTOMEGALOVIRUS
8. ENTEROVIRUSES
9. EPSTEIN-BARR VIRUS
10. GONORRHEA
11. HELICOBACTER PYLORI
12. HEPATITIS
a. Hepatitis A
b. Hepatitis B
c. Hepatitis C
d. Hepatitis D
13. HERPES SIMPLEX VIRUS
Table of Contents (continued)
14. HUMAN HERPES VIRUS-6 (HHV-6)
15. INFLUENZA VIRUSES
16. LEGIONELLA
17. LYME DISEASE
18. MEASLES (RUBEOLA)
19. MENINGITIS
20. MONONUCLEOSIS
21. MUMPS
22. MYCOPLASMA
23. PAPILLOMAVIRUSES
24. PNEUMONIA
25. RESPIRATORY SYNCYTIAL VIRUS (RSV)
26. RHEUMATOID ARTHRITIS
27. ROTAVIRUS (REOVIRUS)
28. RUBELLA (GERMAN MEASLES)
29. SALMONELLOSIS
30. SHIGELLOSIS
31. STAPHYLOCOCCUS AUREUS
32. STREPTOCOCCI
33. SYPHILIS
Instrumentation: Infectious Disease Analyzers Manufactured by:
- Abbott
- Beckman Coulter/Danaher
- bioMeriuex
- Ortho-Clinical Diagnostics
- Roche
- Siemens
- Tosoh
- Wallac, and other suppliers
Current and Emerging Technologies
1. MONOCLONAL ANTIBODIES
2. IMMUNOASSAYS
a. Technological Principle
b. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Dot Immunobinding Assays
- Capillary Immunoassays